Biotechnology
Novo Nordisk Seeks US and EU Approval for Sickle Cell Drug Etavopivat
Novo Nordisk announced US and European regulatory submissions on November 13, 2026, for etavopivat, an investigational once-daily oral treatment for sickle cell disease in adolescents and adults aged 12 years and older. The company submitted a New Drug Application to…
Azitra Q3 Loss Widens to $2.95 Million as Going Concern Doubt Remains
Azitra’s third-quarter results release, issued November 12, 2026, showed a net loss of $2.95 million, compared with $2.76 million a year earlier, as the clinical-stage dermatology company advanced two programs toward data readouts. Cash and cash equivalents totaled $3.75 million…
Aethlon Medical Quarterly Loss Widens as Merger Costs Rise
Aethlon Medical reported a net loss of $2.62 million for the fiscal second quarter ended September 30, 2026, up from $1.49 million a year earlier, in a November 12, 2026 results announcement. Operating expenses rose 77.2%, driven primarily by professional…
Zhengye First-Half Revenue Falls 18.3% as Net Loss Narrows
Zhengye Biotechnology Holding Limited reported first-half revenue of RMB50.9 million (US$7.5 million) in a filing dated November 12, 2026, down 18.3% from a year earlier, as customer losses and cost cutting reduced vaccine sales. Net loss at the Chinese veterinary…
CytoSorbents Reaches Cash-Flow Breakeven Before Restructuring Payments
Blood-purification company CytoSorbents reported on November 12, 2026 that revenue for the quarter ended September 30 rose 3% to $9.7 million, while it generated approximately $43,000 in positive operating cash flow excluding about $251,000 of restructuring-related payments. Total quarterly cash…
PAI Pharma Buys Nexus and Adds More Than 20 Hospital Injectables
PAI Pharma announced the acquisition of Nexus Pharmaceuticals, LLC on November 12, 2026, adding an established commercial portfolio of more than 20 hospital injectable products to its oral-liquid and sterile-injectable operations. Financial terms were not disclosed. Nexus develops and commercializes…
Amyris to Acquire Oobli and Expand Protein Production Capabilities
Amyris announced on November 12, 2026, that it will acquire Oobli, whose fermentation-derived sweet proteins help food and beverage brands reduce sugar without sacrificing taste. Amyris expected the pending transaction to close in the weeks following the announcement. Financial terms…
Twist Bioscience Q4 Revenue Rises 28% With Positive Adjusted EBITDA
Twist Bioscience announced its fiscal 2026 results on November 12, 2026, reporting fourth-quarter revenue of $126.6 million, up 28% from a year earlier, and positive adjusted EBITDA of $2.2 million, a non-GAAP measure the company uses to assess operating trends.…
Lilly Details One-Year Taltz and Zepbound PsA Trial Results
Eli Lilly and Company on November 11, 2026 announced detailed exploratory 52-week results from its TOGETHER-PsA Phase 3b trial. At Week 52, 43.7% of patients receiving Taltz (ixekizumab) plus Zepbound (tirzepatide) achieved ACR50, indicating at least a 50% reduction in…
IASO Bio Wins China IND Approval for IASO208 CAR-T Therapy
IASO Bio announced on November 11, 2026, that China’s National Medical Products Administration had approved the investigational new drug (IND) application for IASO208, its CD20-targeting in vivo CAR-T therapy. The approval moves the company’s InTelliCAR platform into synchronized clinical development…
FDA Approves PIMJETMI With Abbisko Milestone Tied to U.S. Sale
EMD Serono announced on November 10, 2026, that the U.S. Food and Drug Administration had approved PIMJETMI (pimicotinib) for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. The…
Azenta Q4 Revenue Rises 5% as Sample Management Solutions Grows 9%
Azenta’s fourth-quarter and full-year results, published November 10, 2026, showed revenue from continuing operations rising 5% year over year to $167.1 million for the quarter ended September 30, 2026. Adjusted EBITDA, a company-defined profitability measure, fell 7% to $19.4 million,…
New England Biolabs Launches Mammoth’s MB-CasFire Research Enzyme
On November 10, 2026, New England Biolabs (NEB) announced a global licensing agreement with Mammoth Biosciences to manufacture and commercialize MB-CasFire, making the CRISPR enzyme immediately available worldwide for research use through NEB and its distribution network. NEB’s product listing…
Protalix Q3 Product Sales Rise 23.5% as R&D Costs Climb 55%
Protalix BioTherapeutics reported third-quarter revenue of $21.9 million on November 10, 2026, with product sales up 23.5% as Chiesi drove growth. Net income rose to $4.0 million from $2.4 million despite a 55% increase in research and development spending, while…
Beam Sickle Cell Therapy Meets Pivotal Goals Ahead of Planned BLA
Beam Therapeutics announced on November 10, 2026 that ristoglogene autogetemcel (risto-cel), its investigational one-time cell therapy for sickle cell disease, met the primary efficacy and safety endpoints in a prespecified interim analysis of the BEACON Phase 1/2 trial, supporting a…
